Pneumoconiosis secondary prevention

	Pneumoconiosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pneumoconiosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pneumoconiosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pneumoconiosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pneumoconiosis secondary prevention
CDC on Pneumoconiosis secondary prevention
Pneumoconiosis secondary prevention in the news
Blogs on Pneumoconiosis secondary prevention
Directions to Hospitals Treating Pneumoconiosis
Risk calculators and risk factors for Pneumoconiosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD

Overview

Effective measures for the secondary prevention of pneumoconiosis include avoiding further exposure and being vaccinated. ^[1]

Effective measures for the secondary prevention of pneumoconiosis include: ^[2] ^[3] ^[4] ^[5]

↑ Cullinan P, Reid P (2013). "Pneumoconiosis". Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
↑ Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL; et al. (2011). "Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry". Occup Environ Med. 68 (11): 842–8. doi:10.1136/oem.2010.064220. PMC 4347849. PMID 21460389.
↑ Sood A (2009). "Current treatment of chronic beryllium disease". J Occup Environ Hyg. 6 (12): 762–5. doi:10.1080/15459620903158698. PMC 2774897. PMID 19894178.
↑ "IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Silica, Some Silicates, Coal Dust and Para-Aramid Fibrils. Lyon, 15-22 October 1996". IARC Monogr Eval Carcinog Risks Hum. 68: 1–475. 1997. PMC 5366849. PMID 9303953.
↑ Pelucchi C, Pira E, Piolatto G, Coggiola M, Carta P, La Vecchia C (2006). "Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005". Ann Oncol. 17 (7): 1039–50. doi:10.1093/annonc/mdj125. PMID 16403810.